ArticleInternational journal of hepatology2012
In vitro systems for the study of hepatitis C virus infection.
Article in International journal of hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Natural flavonoids effectively block the CD81 receptor of hepatocytes and inhibit HCV infection: a computational drug development approach.Molecular diversity · 2023Article
- Gene Expression Profiling of Different Huh7 Variants Reveals Novel Hepatitis C Virus Host Factors.Viruses · 2019Article
- Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process.Cell host & microbe · 2018Article
- The Application of Humanized Mouse Models for the Study of Human Exclusive Viruses.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection.Frontiers in immunology · 2016Review
- Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection.The Journal of general virology · 2015Article
- Article
- Novel permissive cell lines for complete propagation of hepatitis C virus.Journal of virology · 2014Article
- Bioreactor technologies to support liver function in vitro.Advanced drug delivery reviews · 2014Review
- Alginate hydrogel protects encapsulated hepatic HuH-7 cells against hepatitis C virus and other viral infections.PloS one · 2014Article
- Approaches to hepatitis C treatment and cure using NS5A inhibitors.Infection and drug resistance · 2014Review
- Hepatitis c virus genotype 4 replication in the hepatocellular carcinoma cell line HepG2/C3A.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The study of a virus is made possible by the availability of culture systems in which the viral lifecycle can be realized. Such systems support robust virus entry, replication, assembly, and secretion of nascent virions. Furthermore, culture models provide a platform in which therapeutic interventions can be devised or monitored. Hepatitis C virus (HCV) has a restricted tropism to human and chimpanzees; thus investigations of HCV biology have been hindered for many years due to a lack of small animal models. Nevertheless, significant efforts have been directed at developing cell culture models to elucidate the viral lifecycle in vitro. HCV primarily infects liver parenchymal cells commonly known as hepatocytes. The liver is a highly specialized and complex organ and the development of in vitro systems that reflects this complexity has proven difficult. Consequently, host cell receptor molecules that potentiate HCV infection were identified over a decade after the virus was discovered. A summary of the various HCV in vitro culture models, their advantages, and disadvantages are described.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.